絞り込み

16315

広告

793件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital.

Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence.

[Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation].

Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): Advantages, limitations and future challenges.

Management of bleeding or urgent interventions in patients treated with direct oral anticoagulants (DOACs) - 2017 management proposals in Poland.

[New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].

The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.

Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism.

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.

Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease.

Edoxaban: Defining place in therapy for the newest direct acting oral anticoagulant.

[Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease].

Role of Direct Oral Anticoagulants in the Management of Anticoagulation.

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.

Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.

Anticoagulation Therapy in Children.

Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.

Reversing the anticoagulation effects of dabigatran.

Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります